Latest Temozolomide Stories
The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting.
A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®).
Advocates from across the country joined the National Brain Tumor Society in meeting with congressional leaders to discuss the importance of cancer research funding and oral chemotherapy parity.
- To fire mitraille at.